The FDA is aware that Boston Scientific (BSX) has issued a letter to affected customers recommending all ACCOLADE pacemakers and CRT-Ps be corrected prior to continued use, the agency announced. This recall involves correcting devices, and does not involve removing them from where they are used or sold, the FDA noted.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific Shareholders Approve Directors and Governance Changes
- Why Is SPDR S&P 500 ETF Trust (SPY) Up Today, 5/5/2026?
- Boston Scientific downgraded to Neutral from Outperform at Daiwa
- Boston Scientific price target lowered to $95 from $115 at Argus
- Boston Scientific announces data on Farapulse PFA Platform, Watchman LAAC